Elanco Animal Health, 
a division of Eli Lilly and
Company, is a global research-based company that develops
and markets products to improve the health and production of animals in more
than 75 countries. Elanco is committed to companion and production animals. Elanco products
enhance animal health, wellness and the human-pet bond. Additionally, they increase performance to help the food industry produce an abundant supply of safe and affordable food.
Eli Lilly and Company is a leading innovation-driven corporation
committed to developing a growing portfolio of first-in-class and best-in-class
pharmaceutical products that help people live longer, healthier and more active
lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity
disorder, diabetes, osteoporosis and many other conditions.
Important Safety Information
- The most common adverse reactions recorded during clinical trials with Reconcile® were calm or lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive vocalization, aggression, and, in infrequent cases, seizures.
- Reconcile® chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
- A six week washout interval should be observed following discontinuation of therapy with Reconcile® chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
- For full product label, including complete safety information, click here.
